<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01608542</url>
  </required_header>
  <id_info>
    <org_study_id>D4300C00032</org_study_id>
    <nct_id>NCT01608542</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects</brief_title>
  <official_title>A Phase I, Open-label Study to Assess the Pharmacokinetics of Oral Fostamatinib in Healthy Japanese Subjects After Single and Multiple Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is a single and multiple dose study in healthy male and female (of non-child bearing
      potential) Japanese volunteers, to assess the blood and urine drug levels of Fostamatinib.
      Fostamatinib is being developed for the treatment of rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open-label Study to Assess the Pharmacokinetics of Oral Fostamatinib in Healthy
      Japanese Subjects After Single and Multiple Doses
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of fostamatinib from blood and urine in terms of AUC; tmax; Cmax; t1/2 and Rac.</measure>
    <time_frame>PK sampling at predose, 0, 0.25, 0.5, 1,1.5, 2, 4, 6, 8,12, 16, 24, 36, 48 and 72 hours post-dose following the single dose (on Day 1) and after repeated twice daily dosing on Days 4 and 10</time_frame>
    <description>AUC - area under the plasma concentration time curve from zero to infinity ; tmax - time to max plasma concentration; t1/2 - terminal elimination half life; Rac - accumulation ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability profile in terms of adverse event monitoring, vital signs, physical examinations, clinical laboratory tests, 12 lead ECG</measure>
    <time_frame>Up to Day 20</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Japanese Volunteers</condition>
  <arm_group>
    <arm_group_label>Fostamatinib 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to two cohorts of Japanese subjects are planned to receive fostamatinib 100mg single and multiple twice daily doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fostamatinib 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to two cohorts of Japanese subjects are planned to receive fostamatinib 200mg single and multiple twice daily doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib 100mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Fostamatinib 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib 200mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Fostamatinib 200mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female (of non-childbearing potential) Japanese subjects

          -  20 to 45 years of age

          -  Body mass index (BMI) between 17 and 27 kg/m2 and weigh at least 45 kg and no more
             than 100 kg

        Exclusion Criteria:

          -  History or presence of respiratory, GI, renal, hepatic, hematological, lymphatic,
             neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary,
             immunological, dermatological, connective tissue diseases or disorders

          -  Any clinically significant illness, acute infection, known inflammatory process,
             medical/surgical procedure or trauma within 4 weeks of the first administration of
             investigational product

          -  Smoking in excess of 5 cigarettes per day or equivalent within 30 days of Day 1

          -  Use of prescription or over-the-counter drugs within 2 weeks of first administration
             of investigational product

          -  Previous participation in a fostamatinib study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Layton, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase/California Clinical Trials Medical Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <last_update_submitted>December 18, 2012</last_update_submitted>
  <last_update_submitted_qc>December 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fostamatinib</keyword>
  <keyword>FosD</keyword>
  <keyword>Japanese Healthy volunteers</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Single and Multiple Dose Study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

